Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cognition Therapeutics Inc (CGTX)

Cognition Therapeutics Inc (CGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,281
  • Shares Outstanding, K 41,548
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,790 K
  • EBIT $ -58 M
  • EBITDA $ -58 M
  • 60-Month Beta 1.34
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.23
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.97
  • Most Recent Earnings $-0.25 on 11/13/24
  • Next Earnings Date 11/14/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.14
  • Low Estimate -0.34
  • Prior Year -0.27
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4264 +2.65%
on 11/19/24
0.6500 -32.66%
on 10/23/24
-0.0323 (-6.87%)
since 10/21/24
3-Month
0.3400 +28.74%
on 10/11/24
0.8196 -46.60%
on 08/22/24
-0.3121 (-41.62%)
since 08/21/24
52-Week
0.3400 +28.74%
on 10/11/24
2.9500 -85.16%
on 05/23/24
-0.5623 (-56.23%)
since 11/21/23

Most Recent Stories

More News
Cognition Therapeutics Reports Financial Results for the Third Quarter 2024 and Provides Business and Clinical Update

CGTX : 0.4400 (unch)
Cognition Therapeutics to Present at Zacks SCR Life Sciences Investor Forum

CGTX : 0.4400 (unch)
November’s Small-Cap Treasures: 3 Stocks Poised for Growth

Three promising small-cap stocks, poised for growth in healthcare, cybersecurity, and renewable energy, offer compelling investment opportunities for November.

LODE : 0.3489 (+0.40%)
CGTX : 0.4400 (unch)
ASNS : 1.1907 (+0.06%)
Cognition Therapeutics Presents Poster of Participant Demographics from Phase 2 Dementia with Lewy Bodies Study at CTAD

CGTX : 0.4400 (unch)
Cognition Therapeutics Announces Results of Pre-specified Analysis of SHINE Study Data Presented at CTAD

CGTX : 0.4400 (unch)
Analyses from Cognition’s Positive Phase 2 ‘SHINE’ Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease will be Presented in a Podium Presentation at CTAD

CGTX : 0.4400 (unch)
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Executing Clinical Research in Dementia with Lewy Bodies (DLB)

CGTX : 0.4400 (unch)
Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Ongoing Patient Dosing in SHIMMER Study for DLB and SHINE Study for Alzheimer’s DiseasePositive Preliminary Data for Dry AMD Program Presented at ARVO...

CGTX : 0.4400 (unch)
Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

Presented at Alzheimer’s Association International Conference August 4, 2022...

CGTX : 0.4400 (unch)
Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

 - Analyses Demonstrate CT1812 Impact on Alzheimer’s Disease Processes - NEW YORK, July 19, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc....

CGTX : 0.4400 (unch)

Business Summary

Cognition Therapeutics Inc.is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Cognition Therapeutics Inc.is based in PURCHASE,...

See More

Key Turning Points

3rd Resistance Point 0.5054
2nd Resistance Point 0.4899
1st Resistance Point 0.4650
Last Price 0.4400
1st Support Level 0.4246
2nd Support Level 0.4091
3rd Support Level 0.3842

See More

52-Week High 2.9500
Fibonacci 61.8% 1.9530
Fibonacci 50% 1.6450
Fibonacci 38.2% 1.3370
Last Price 0.4400
52-Week Low 0.3400

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar